- Moushib, Laith Ibrahim
- Moreno-Ruiz, Nerea
- Urban Vargas, Blanca Angélica
- Aguiló Cucurull, Aina
- Martin, Andrea
- Rivière, Jacques G.
- Dieli-Crimi Vinuesa, Romina
- Perurena-Prieto, Janire
- Soler-Palacin, Pere
- Colobran, Roger
- Batlle-Masó, Laura
Artificial intelligence; Genetic diagnosis; Inborn errors of immunity, Inteligencia artificial; Diagnóstico genético; Errores congenitos de la inmunidad, Intel·ligència artificial; Diagnòstic genètic; Errors congènits de la immunitat, Introduction: Next-generation sequencing (NGS) has transformed the genetic diagnosis of human diseases, yet many patients remain unsolved due to the complexity of variant interpretation. Manual curation of candidate variants is effective but time-consuming and requires specialized expertise. Artificial intelligence (AI)-driven platforms have emerged as scalable tools for variant prioritization, yet their performance compared with manual curation remains insufficiently evaluated. The aim of this study was to evaluate the performance of AI-driven platforms for variant prioritization in a cohort of patients with inborn errors of immunity (IEI) and to compare their strengths and limitations with manual curation.Methods: We analyzed 22 unsolved IEI cases that had previously undergone inconclusive NGS studies. Whole-genome sequencing was performed, and variant prioritization was carried out using two AI-driven platforms -AIMARRVEL and AION (Nostos Genomics)- and by manual curation. Selected variants were classified according to clinical relevance (very high, high, medium, or low), integrating both molecular and phenotypic evidence.Results: Across the cohort, AI platforms efficiently prioritized variants with clear pathogenic features, often reaching the same conclusions as manual curation but in a fraction of the time. One patient (5%) received a conclusive diagnosis (FAM111B), and four patients (18%) carried variants of high clinical relevance, including strong disease-causing candidates in CD247 and SH2B3. Additional medium-relevance variants were identified in 36% of cases, although evidence was insufficient for functional validation. Notably, concordance between AIMARRVEL and AION was limited, particularly for variants of uncertain significance (VUS), reflecting differences in algorithmic weighting of variant features versus clinical phenotype. Both platforms also highlighted potentially novel associations in RUNX1 and TRAF7, underscoring their capacity to extend beyond classical IEI genes.Discussion: Our results show that AI-driven tools are powerful for detecting clearly pathogenic variants and can markedly accelerate the diagnostic process. However, their strong reliance on curated databases, limited incorporation of phenotypic data, and challenges in handling VUS may reduce their effectiveness. Enhancing phenotype integration, expanding annotations (including non-coding regions), and incorporating up-to-date literature could improve their performance. Ultimately, AI tools should complement expert curation, with future models evolving toward integrative approaches that better capture the complexity of human disorders., The author(s) declared that financial support was received for this work and/or its publication. This study was funded by Instituto de Salud Carlos III, grants PI20/00761 and PI23/00161, co-financed by the European Regional Development Fund (ERDF); and by the Jeffrey Modell Foundation. This research is supported by the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN-RITA). LM acknowledges support from The Swedish Board of Student Finance (CSN); NM-R was supported by grant 2021 FI_B_00296 from Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya; and LB-M is supported by an ISCIII postdoctoral fellowship, “Sara Borrell,” CD24/00011, co-financed by the European Union. Some of the samples were analyzed using the AION platform, supported by the AION Research Grant Program (Nostos) awarded to the Translational Immunology Research Group at VHIR. None of the sponsors has been involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.